AU708886B2 - Tumor necrosis factor (TNF) inhibiting pharmaceuticals - Google Patents

Tumor necrosis factor (TNF) inhibiting pharmaceuticals Download PDF

Info

Publication number
AU708886B2
AU708886B2 AU69420/96A AU6942096A AU708886B2 AU 708886 B2 AU708886 B2 AU 708886B2 AU 69420/96 A AU69420/96 A AU 69420/96A AU 6942096 A AU6942096 A AU 6942096A AU 708886 B2 AU708886 B2 AU 708886B2
Authority
AU
Australia
Prior art keywords
alkyl
hydrogen
compound
branched
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU69420/96A
Other languages
English (en)
Other versions
AU6942096A (en
Inventor
Ruth Gallily
Raphael Mechoulam
Esther Shohami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU6942096A publication Critical patent/AU6942096A/en
Application granted granted Critical
Publication of AU708886B2 publication Critical patent/AU708886B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU69420/96A 1995-09-11 1996-09-10 Tumor necrosis factor (TNF) inhibiting pharmaceuticals Ceased AU708886B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11524595A IL115245A (en) 1995-09-11 1995-09-11 Tumor necrosis factor inhibiting pharmaceuticals
IL115245 1995-09-11
PCT/IL1996/000108 WO1997011668A2 (en) 1995-09-11 1996-09-10 TUMOR NECROSIS FACTOR ALPHA (TNF-α) INHIBITING PHARMACEUTICALS

Publications (2)

Publication Number Publication Date
AU6942096A AU6942096A (en) 1997-04-17
AU708886B2 true AU708886B2 (en) 1999-08-12

Family

ID=11067971

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69420/96A Ceased AU708886B2 (en) 1995-09-11 1996-09-10 Tumor necrosis factor (TNF) inhibiting pharmaceuticals

Country Status (9)

Country Link
US (3) US5932610A (enExample)
EP (1) EP0876143B1 (enExample)
JP (1) JP2000500737A (enExample)
AT (1) ATE331503T1 (enExample)
AU (1) AU708886B2 (enExample)
CA (1) CA2231764A1 (enExample)
DE (1) DE69636308T2 (enExample)
IL (1) IL115245A (enExample)
WO (1) WO1997011668A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
CA2340445A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
CN1377261A (zh) 1999-03-22 2002-10-30 免疫力药品有限公司 治疗免疫疾病
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
WO2001028329A1 (en) 1999-10-18 2001-04-26 University Of Connecticut Peripheral cannabinoid receptor (cb2) selective ligands
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6531128B1 (en) * 2000-02-08 2003-03-11 Pharmacia Corporation Methods for treating glaucoma
AU2001237939A1 (en) * 2000-02-08 2001-08-20 Gulgun Tezel Methods for treating glaucoma
CA2408408C (en) 2000-05-12 2013-07-09 Genzyme Corporation Modulators of tnf- alpha signaling
EP1785417A3 (en) * 2000-06-22 2007-08-01 Pharmos Corporation Novel non-psychotropic cannabinoids
CA2411585A1 (en) * 2000-06-22 2001-12-27 Pharmos Corporation Novel non-psychotropic cannabinoids
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
AU2001296402A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US6541510B2 (en) * 2000-09-28 2003-04-01 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
US7329651B2 (en) * 2001-01-26 2008-02-12 University Of Connecticut Cannabimimetic ligands
WO2002060447A1 (en) 2001-01-29 2002-08-08 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
WO2003005960A2 (en) * 2001-07-13 2003-01-23 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
WO2003035005A2 (en) * 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
US20050137251A1 (en) * 2002-03-18 2005-06-23 Aaron Garzon Dexanabinol and dexanabinol analogs regulate inflammation related genes
WO2003080043A1 (en) * 2002-03-18 2003-10-02 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes
AU2003265663A1 (en) 2002-08-23 2004-03-11 University Of Connecticut Keto cannabinoids with therapeutic indications
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
AU2003291143A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
DE60335652D1 (de) * 2002-11-21 2011-02-17 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
EP1567513A2 (en) * 2002-12-04 2005-08-31 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical copositions
EP2578561A1 (en) * 2005-09-29 2013-04-10 Albany Molecular Research, Inc. Processes for the production of cannabidiol derivatives and intermediates thereof
WO2009059277A1 (en) * 2007-11-02 2009-05-07 University Of South Florida Synergistic modulation of microglial activation by nicotine and thc
GB0915877D0 (en) 2009-09-10 2009-10-14 E Therapeutics Plc Cancer cell apoptosis
GB201207305D0 (en) 2012-04-26 2012-06-13 E Therapeutics Plc Therapy
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US20170038184A1 (en) 2015-08-06 2017-02-09 Charles E. Ankner Formulation delivery system
WO2017068349A1 (en) * 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80411A (en) * 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
US5284867A (en) * 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
WO1994012667A1 (en) * 1992-11-27 1994-06-09 The United States Department Of The Army Inhibitors of arachidonic acid metabolites for preventing neurological damage

Also Published As

Publication number Publication date
JP2000500737A (ja) 2000-01-25
CA2231764A1 (en) 1997-04-03
ATE331503T1 (de) 2006-07-15
WO1997011668A3 (en) 1997-05-15
US6331560B1 (en) 2001-12-18
US6545041B2 (en) 2003-04-08
IL115245A0 (en) 1995-12-31
EP0876143B1 (en) 2006-06-28
US5932610A (en) 1999-08-03
DE69636308D1 (de) 2006-08-10
EP0876143A2 (en) 1998-11-11
US20020049245A1 (en) 2002-04-25
DE69636308T2 (de) 2007-05-31
IL115245A (en) 2002-12-01
EP0876143A4 (en) 2001-06-27
WO1997011668A2 (en) 1997-04-03
AU6942096A (en) 1997-04-17

Similar Documents

Publication Publication Date Title
US5932610A (en) Tumor necrosis factor α (TNF-α) inhibiting pharmaceuticals
US5284867A (en) NMDA-blocking pharmaceutical compositions
US4507323A (en) Treatment of psychosexual dysfunctions
AU2002225026B2 (en) Essential N-3 fatty acids in cardiac insufficiency and heart failure therapy
JP6076737B2 (ja) 高血圧症の防止及び治療のための組成物並びに方法
JP3114895B2 (ja) 炎症性疾患の処置のための薬剤調製物
CN108472275A (zh) 治疗缺血性中风的组合物及方法
US5175187A (en) Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof
CA2136977A1 (en) _-8-tetrahydro-cannabinol as antiemetic
KR20260011783A (ko) 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 비알코올성 지방간 질환 예방 또는 치료용 약학적 조성물
KR20250152044A (ko) 멜리사엽 분획 추출물 및 이를 포함하는 신규 약학적 조성물
US6916849B2 (en) Compositions for improving lipid content in the blood
JPH0768235B2 (ja) Ｎｍｄａ遮断薬剤組成物
US20090068143A1 (en) Orally effective cannabinoid analogs
US20240269104A1 (en) Method for treating parkinson's disease
De Kozak et al. Ginkgo biloba extract (EGb 761) and a platelet-activating factor antagonist protect the retina in experimental autoimmune uveoretinitis
US5252600A (en) Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof
CN105535007A (zh) 淫羊藿苷及其衍生物用于预防和治疗精神障碍的用途
JPH07165588A (ja) 脳機能改善剤
AU2023327823A1 (en) Cannabidiol for use in treating or preventing recurrent pericarditis
CN118892483A (zh) 一种mpo酶抑制剂在制备预防和/或治疗神经炎症疾病药物中的应用
CN121714621A (zh) 香青兰总黄酮在制备预防或治疗自身免疫性脱髓鞘疾病药物中的应用
CN121754576A (zh) 滨蒿总黄酮在制备预防或治疗自身免疫性脱髓鞘疾病药物中的应用
JP2001253825A (ja) 帯状疱疹後神経痛用鎮痛剤
JPH05938A (ja) 肺炎予防または治療剤